RAPID DOSE THERAPEUTICS DONATES QUICKSTRIP™ VITAMIN B12 NUTRACEUTICAL PRODUCT TO COMMUNITY

BURLINGTON, Ontario, April 02, 2020 (GLOBE NEWSWIRE) — Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) in response to the COVID pandemic, recently made a donation to the Burlington Foodbank contributing over 16,000 QuickStrip™ Vitamin B12 product to distribute to those in need in the community, to support overall general health in these unprecedented times.

Vitamin B12 can help in red blood cell formation, cell metabolism, nerve function and maintaining healthy nervous and cardiovascular systems. Combined, these factors can contribute to a healthy immune system that is ready to help fight off illness.

RDT’s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral, fast-dissolving drug delivery system that offers consumers an “anytime, anywhere” solution.

To further our commitment to our customers, RDT is continuing to operate while carefully considering the safety of our employees and customers. As the COVID-19 pandemic continues to evolve and have an impact across the country, RDT is placing the utmost priority in our effort to keep our customers and team members safe while minimizing the risk of any possible transmission in the communities where we live and work. RDT continues to monitor the situation closely and is prepared to respond quickly and appropriately to the rapidly changing nature of this pandemic.

About Rapid Dose Therapeutics

Rapid Dose Therapeutics Corp. is a publicly traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. Within the cannabis sector, RDT provides a turn-key business solution which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. RDT is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.

For more information, visit: www.rapid-dose.com

For further inquiries please contact:

Mark Upsdell
CEO
[email protected]
(647) 200-4709

Social Media
RapidDoseTherapeutics.linkedin
RapidDoseTherapeutics.twitter
RapidDoseTherapeutics.facebook
QuickStrip.instagram

Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “will”, “could”, “are planned to”, “are expected to” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the Corporation’s retail sales of nutraceutical products, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; the ability to implement its business strategies; competition; and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.